Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1580300 | 0.99 | PDE4B (0.53) | PDE4BPDE4DALDH1A1KDM4EHPGD | |
| SCHEMBL12388579 | 0.95 | KDM4E (0.54) | PDE4BPDE4DALDH1A1KDM4EHPGD | |
| Hydrochloric Acid SCHEMBL1580067 | 0.94 | KDM4E (0.53) | PDE4BPDE4DALDH1A1KDM4EHPGD | |
| Hydrochloric Acid SCHEMBL1579914 | 0.89 | PDE4B (0.53) | PDE4BPDE4DSMN1; SMN2MEN1KMT2A | |
| SCHEMBL12237375 | 0.84 | MAPK1 (0.52) | PDE4BPDE4DKDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1580247 | 0.83 | MAPK1 (0.51) | PDE4BPDE4DKDM4EMEN1KMT2A | |
| SCHEMBL13425100 | 0.79 | MAPT (0.58) | ALDH1A1KDM4EMEN1KMT2ATSHR | |
| SCHEMBL1554272 | 0.79 | MAPT (0.54) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL2338247 | 0.79 | TSHR (0.46) | PDE4BPDE4DALDH1A1KDM4EHPGD | |
| SCHEMBL28648073 | 0.77 | ALDH1A1 (0.52) | PDE4BPDE4DALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301146-A1 | GLYCOGEN SYNTHASE KINASE-3 BETA INHIBITORS CONTAINING 7-HYDROXY-BENZOIMIDAZOLE-4-YL-METHANONE DERIVATIVES | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-12-08 | — | — | US | disclosed |
| US-20110301146-A1 | GLYCOGEN SYNTHASE KINASE-3 BETA INHIBITORS CONTAINING 7-HYDROXY-BENZOIMIDAZOLE-4-YL-METHANONE DERIVATIVES | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-12-08 | — | — | US | disclosed |
| US-20110263566-A1 | 7-Hydroxy-benzoimidazole-4-yl-methanone Derivatives and PBK Inhibitors Containing the Same | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263566-A1 | 7-Hydroxy-benzoimidazole-4-yl-methanone Derivatives and PBK Inhibitors Containing the Same | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110190351-A1 | Benzoimidazole Derivatives and Glycogen Synthase Kinase-3 Beta Inhibitors Containing the Same | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-08-04 | — | — | US | disclosed |
| US-20110190351-A1 | Benzoimidazole Derivatives and Glycogen Synthase Kinase-3 Beta Inhibitors Containing the Same | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-08-04 | — | — | US | disclosed |
| WO-2010058512-A1 | GLYCOGEN SYNTHASE KINASE-3 BETA INHIBITORS CONTAINING 7-HYDROXY-BENZOIMIDAZOLE-4-YL-METHANONE DERIVATIVES | ONCOTHERAPY SCIENCE, INC. (JP) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263566-A1 | 7-Hydroxy-benzoimidazole-4-yl-methanone Derivatives and PBK Inhibitors Containing the Same | PDXK, BCKDK, SBK1 | PDE4B 2687/4885PDE4D 3525/4885ALDH1A1 3422/4885 |
| US-20110301146-A1 | GLYCOGEN SYNTHASE KINASE-3 BETA INHIBITORS CONTAINING 7-HYDROXY-BENZOIMIDAZOLE-4-YL-METHANONE DERIVATIVES | GSK3B, GSK3A, GYS2 | PDE4B 1718/4885PDE4D 2286/4885ALDH1A1 2795/4885 |
| US-20110190351-A1 | Benzoimidazole Derivatives and Glycogen Synthase Kinase-3 Beta Inhibitors Containing the Same | GSK3B, GSK3A, GYS2 | PDE4B 1840/4885PDE4D 1792/4885ALDH1A1 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.